뒤로
Leap Therapeutics Inc(LPTX) 가격
LPTX 주가 차트
LPTX 수입
Leap Therapeutics Inc
$1.06
-3.63%
$-0.04
종가: Jan 20, 16:00:00 GMT-5
$1.06
0%
$0
애프터마켓: Jan 20, 20:00:00 GMT-5
주요 통계
이전 종가
$1.1
시가
$1.07
일일 범위
$1.03 - $1.09
52주 범위
$0.2223 - $3.69
거래량
84.4K
평균 거래량
15.7M
EPS(TTM)
-1.58
배당수익률
--
시가총액
$60.0M
LPTX란 무엇인가요?
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The firm is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The firm also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
